24.04.2013
Amgen Inc Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Price/Volume
Valuation Analysis Latest Fiscal Year: LTM as of: 52-Week High (23.04.2013) 52-Week Low (01.06.2012) Daily Volume Current Price (4/dd/yy) 52-Week High % Change 52-Week Low % Change % 52 Week Price Range High/Low Shares Out 18.02.2013 Market Capitalization Total Debt Preferred Stock Minority Interest Cash and Equivalents Enterprise Value Relative Stock Price Performance AMGN UW EQUITY YTD Change AMGN UW EQUITY YTD % CHANGE
12/2012 03/yy 114.95 67.61 724'876.00 105.18 -7.59% 55.57% 95.37% 748.4 78'719.87 26'541.00 0.0 0.0 24'061.00 81'340.87
Total Revenue TEV/Revenue EBITDA TEV/EBITDA Net Income P/E
6.0 M
100
5.0 M
80
4.0 M
60
3.0 M
40
2.0 M
20
1.0 M
0 a-12 m-12
j-12
j-12
a-12
s-12
o-12
n-12
d-12
j-13
f-13 m-13
Market Data Dividend Yield Beta Equity Float Short Int 1 Yr Total Return YTD Return Adjusted BETA Analyst Recs Consensus Rating Average Daily Trading Volume Average Volume 5 Day - Average Volume 30 Day - Average Volume 3 Month
Fiscal Year Ended 31.12.2008 15'003.0 4.02x 6'287.0 9.59x 4'052.0 12.89x
120
31.12.2009 31.12.2010 14'642.0 15'053.0 3.65x 3.13x 6'728.0 6'679.0 7.94x 7.05x 4'605.0 4'627.0 11.71x 11.68x Profitability
LTM-4Q 31.12.2011 15'582.0 3.33x 5'372.0 9.66x 3'683.0 12.87x
EBITDA EBIT Operating Margin Pretax Margin Return on Assets Return on Common Equity Return on Capital Asset Turnover Margin Analysis Gross Margin EBITDA Margin EBIT Margin Net Income Margin Structure Current Ratio Quick Ratio Debt to Assets Tot Debt to Common Equity Accounts Receivable Turnover Inventory Turnover
31.12.2012 17'265.0 3.92x 6'665.0 10.15x 4'345.0 14.37x 6'665.00 5'577.00 32.30% 29.01% 9.11% 23.95% 12.22% 0.35% 83.1% 38.6% 31.8% 25.2% 3.81 3.24 48.88% 139.25% 6.33 1.14
Price/ Cash Flow
LTM
03/yy 15'924.0 12.60x 5'542.0 9.95x 3'742.0 12.97x
03/yy 17'455.0 15.53x 4'929.0 0.00x 4'595.0 16.11x
FY+1
.0 M a-13
1.37 0.73 747.54 10.25 56.22% 22.52% 0.726 32 3.813 1'740'029 1'642'546 1'719'554 FY+2
FQ+1
FQ+2
12/13 Y 12/14 Y 06/13 Q2 09/13 Q3 17'946.8 18'388.2 4'499.4 4'557.1 4.18x 3.89x 7'358.0 8'244.5 1'637.5 1'713.5 11.04x 9.86x 5'537.7 6'203.0 1'340.3 1'377.4 14.47x 12.72x 14.21x 13.52x S&P Issuer Ratings
Long-Term Rating Date Long-Term Rating Long-Term Outlook Short-Term Rating Date Short-Term Rating Credit Ratios EBITDA/Interest Exp. (EBITDA-Capex)/Interest Exp. Net Debt/EBITDA Total Debt/EBITDA Reference Total Debt/Equity Total Debt/Capital Asset Turnover Net Fixed Asset Turnover Accounts receivable turnover-days Inventory Days Accounts Payable Turnover Day Cash Conversion Cycle
07.09.2007 A+ STABLE 31.05.2012 A-1+ 6.18 5.54 0.37 3.98 139.2% 58.2% 0.35 3.27 57.67 320.34 341.43 296.17
Sales/Revenue/Turnover
14.00
20'000.0 18'000.0
12.00
16'000.0
10.00
14'000.0 12'000.0
8.00
10'000.0 8'000.0
6.00
6'000.0
4.00
4'000.0 2.00 0.00 01.01.2010
2'000.0 0.0 01.07.2010
01.01.2011
01.07.2011
01.01.2012
01.07.2012
01.01.2013
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Q.M.S Advisors | tel: +41 (0)78 922 08 77 | e-mail: info@qmsadv.com |